Global mAb Biosimilars Market 2016-2020 - Product Image

Global mAb Biosimilars Market 2016-2020

  • ID: 3883936
  • Report
  • Region: Global
  • 103 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • 3SBio
  • Allergan
  • Amgen
  • AstraZeneca
  • Bharat Serums
  • Biogen
  • MORE
About Biosimilars

Biosimilars or follow-on biologics are generic versions of the biopharmaceutical products. These are developed following the patent expiry of an original molecule. Biosimilars have the same biological properties as original drugs and target the same diseases. They have many similarities but are not identical to the reference biopharmaceutical product.

The analysts forecast the spending on the global monoclonal antibody (mAb) biosimilars market to grow at a CAGR of 4-7% during the period 2015-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global monoclonal antibody (mAb) biosimilars market 2016-2020. To calculate the market size, the report considers the report considers the revenue generated from the sales of mAbs. The report also considers the revenues generated from the sales of drugs that are expected to be launched during the forecast period.

The market is divided into the following segments based on geography:
- Europe
- Asia
- ROW

The report, Global Monoclonal Antibody (mAb) Biosimilars Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Biocon
- Celltrion
- Dr. Reddy's Laboratories
- Hospira

Other prominent vendors
- 3SBio
- Accord Healthcare
- AET Biotech
- Allergan
- Alvartis Pharma
- Amega Biotech
- Amgen
- Apotex
- Aspen
- AstraZeneca
- Aurobindo Pharma
- Baxter
- Bharat Serums
- Bio Sidus
- Biogen
- Bionovis
- Bioton
- BioXpress Therapeutics
- Boehringer Ingelheim
- Boston Oncology
- Cipla
- Coherus Biosciences
- Daiichi Sankyo
- Emcure Pharmaceuticals
- Gedeon Richter
- GeneScience Pharmaceuticals
- GSK
- Hetero Drugs
- iBio
- Intas Pharmaceuticals
- JCR Pharmaceuticals
- LG Lifesciences
- Lonza
- Merck
- Mitsubishi Tanabe Pharma
- Momenta Pharmaceuticals
- Mylan
- Natco Pharma
- Novartis
- Pfenex
- Pfizer
- Ranbaxy Laboratories
- Roche Holding
- Samsung Biologics
- Sanofi
- Synthon

Market driverssss
- Rise in number of patent expiries
- For a full, detailed list, view the full report

Market challengessss
- Physicians' reluctance to prescribe biosimilars
- For a full, detailed list, view the full report

Market trends
- Emergence of biosimilars
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3SBio
  • Allergan
  • Amgen
  • AstraZeneca
  • Bharat Serums
  • Biogen
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
  • Assumptions
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
  • Biosimilars: Overview
  • Comparative analysis of generic small molecules and biosimilars
  • Biosimilars market opportunities
  • Challenges for new entrants
  • Bio-betters
PART 05: Pipeline portfolio

PART 06: Market landscape
  • Market overview
  • Five forces analysis
PART 07: Market segmentation by application
  • Global chronic and autoimmune diseases mAb biosimilars market
  • Global oncology mAb biosimilars market
PART 08: Geographical segmentation
  • Global mAb biosimilars market by geographical segmentation 2015-2020
  • mAb biosimilars market in Europe
  • mAb biosimilars market in Asia
  • mAb biosimilars market in rest of the world
PART 09: Market drivers
  • Rise in number of patent expiries
  • Need for cost-effective treatment
  • Reimbursement benefits for biosimilars
  • Favorable government regulations
PART 10: Impact of drivers

PART 11: Market challenges
  • Physicians' reluctance to prescribe biosimilars
  • Multiple manufacturing complexities
  • Risks related to drug failure
  • Limited availability of biosimilar products
  • Difficulties in patient recruitment for clinical trials
PART 12: Impact of drivers and challenges

PART 13: Market trends
  • Emergence of biosimilars
  • Outsourcing of manufacturing activities
  • Need for high investment in R&D
  • High growth in the emerging markets
  • Rising number of strategic collaborations
PART 14: Vendor landscape
  • Competitive scenario
PART 15: Key vendor analysis
  • Biocon
  • Celltrion
  • Dr. Reddy's Laboratories
  • Hospira
  • Other prominent vendors
PART 16: Appendix
  • List of abbreviations
PART 17: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Global mAb biosimilars market: Snapshot
Exhibit 03: Global mAb biosimilars market: Growth analysis
Exhibit 04: Global mAb biosimilars market: Key buying criteria 2015
Exhibit 05: Global mAb biosimilars market: Timeline 2014-2020
Exhibit 06: Global mAb biosimilars market: Impact of key customer segments 2015
Exhibit 07: Definition of biosimilars by agencies
Exhibit 08: Comparison between generic small molecules and biosimilars
Exhibit 09: Impact of biosimilars cost savings on different sectors
Exhibit 10: Factors affecting success of biosimilars
Exhibit 11: Biosimilars industry: Point-of-view
Exhibit 12: Factors influencing uptake of biosimilars
Exhibit 13: Global mAb biosimilars market: Strategic factors for new market entrants
Exhibit 14: Challenges for new entrants
Exhibit 15: Bio-betters and its impact on market
Exhibit 16: Global mAb biosimilars market: Pipeline snapshot 2015
Exhibit 17: Pipeline portfolio: Global mAb biosimilars market 2015
Exhibit 18: Patent expiry in key mAb biosimilars markets 2000-2020
Exhibit 19: Global mAb biosimilars market: Developed and emerging markets 2015
Exhibit 20: Global mAb biosimilars market 2015-2020 ($ millions)
Exhibit 21: Biosimilars: Savings potential in five European countries and US ($ billions) 2016-2020
Exhibit 22: Global spending on mAb biosimilars 2010-2020 ($ billions)
Exhibit 23: Global mAb biosimilars market: Key metrics analysis snapshot
Exhibit 24: Current and future trends in global mAb biosimilars market
Exhibit 25: Factors influencing the global mAb biosimilars market 2015
Exhibit 26: Five forces analysis
Exhibit 27: Global mAb biosimilars market: Segmentation by application (2015-2020)
Exhibit 28: Applications of mAb biosimilars and its impact on growth of market
Exhibit 29: Global mAb biosimilars market segmentation: Growth cycle analysis
Exhibit 30: Population aged 60 years and over (millions)
Exhibit 31: Global chronic and autoimmune diseases mAb biosimilars market 2015-2020 ($ millions)
Exhibit 32: Opportunity analysis of chronic and autoimmune diseases mAb biosimilars market by application
Exhibit 33: Global incidence of cancer 2015-2020 (millions)
Exhibit 34: Global oncology mAb biosimilars market 2015-2020 ($ millions)
Exhibit 35: Opportunity analysis of global oncology mAb biosimilars market by type of application
Exhibit 36: Global mAb biosimilars market segmentation by application 2015
Exhibit 37: Global mAb biosimilars market by geography: Outlook 2015-2020
Exhibit 38: Global mAb biosimilars market by geography 2015
Exhibit 39: Market penetration of originators and biosimilars by region/country
Exhibit 40: Global mAb biosimilars market landscape: Country analysis
Exhibit 41: mAb biosimilars market in Europe: Opportunity analysis
Exhibit 42: mAb biosimilars market in Europe 2015-2020 ($ millions)
Exhibit 43: PEST analysis: mAb biosimilars market in Europe 2015
Exhibit 44: mAb biosimilars market in Asia: Opportunity analysis
Exhibit 45: mAb biosimilars market in Asia 2015-2020 ($ millions)
Exhibit 46: PEST analysis: mAb biosimilars market in Asia 2015
Exhibit 47: mAb biosimilars market in rest of the world: Opportunity analysis
Exhibit 48: mAb biosimilars market in rest of the world 2015-2020 ($ millions)
Exhibit 49: Benefits of mAb biosimilars to US healthcare system
Exhibit 50: PEST analysis: mAb biosimilars market in rest of the world 2015
Exhibit 51: Impact of drivers and challenges on global mAb biosimilars market
Exhibit 52: Patent analysis of mAb in the US
Exhibit 53: Patent analysis of biologicals in Europe
Exhibit 54: Impact of drivers
Exhibit 55: Physicians' reluctance to prescribe biosimilars: Key reasons
Exhibit 56: Impact of drivers and challenges
Exhibit 57: Global mAb biosimilars market: Impact assessment of key trends
Exhibit 58: Competitive assessment of vendors
Exhibit 59: Key vendors: Geographical presence 2015
Exhibit 60: Major vendors in global mAb biosimilars market: Mergers, acquisitions, and partnerships
Exhibit 61: Biocon profile
Exhibit 62: Biocon: Metrics analysis
Exhibit 63: Biocon growth strategy matrix
Exhibit 64: Biocon: Opportunity assessment
Exhibit 65: Celltrion profile
Exhibit 66: Celltrion: Metrics analysis
Exhibit 67: Celltrion growth strategy matrix
Exhibit 68: Celltrion: opportunity assessment
Exhibit 69: Dr. Reddy's Laboratories profile
Exhibit 70: Dr. Reddy's Laboratories: Metrics analysis
Exhibit 71: Dr. Reddy's Laboratories growth strategy matrix
Exhibit 72: Dr. Reddy's Laboratories Opportunity assessment
Exhibit 73: Hospira profile
Exhibit 74: Hospira: Metrics analysis
Exhibit 75: Hospira growth strategy matrix
Exhibit 76: Hospira opportunity growth assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 3SBio
  • Allergan
  • Amgen
  • AstraZeneca
  • Bharat Serums
  • Biogen
  • MORE
New Report Released: – Global Monoclonal Antibody (mAb) Biosimilars Market 2016-2020

The author of the report recognizes the following companies as the key players in the Global Monoclonal Antibody (mAb) Biosimilars Market: Biocon, Celltrion, Dr. Reddy's Laboratories, Hospira, 3SBio, Accord Healthcare, AET Biotech, Allergan, Alvartis Pharma, Amega Biotech, Amgen, Apotex, Aspen, AstraZeneca, Aurobindo Pharma, Baxter, Bharat Serums, Bio Sidus, Biogen, Bionovis, Bioton, BioXpress Therapeutics, Boehringer Ingelheim, Boston Oncology, Cipla, Coherus Biosciences, Daiichi Sankyo, Emcure Pharmaceuticals, Gedeon Richter, GeneScience Pharmaceuticals, GSK, Hetero Drugs, iBio, Intas Pharmaceuticals, JCR Pharmaceuticals, LG Lifesciences, Lonza, Merck, Mitsubishi Tanabe Pharma, Momenta Pharmaceuticals, Mylan, Natco Pharma, Novartis, Pfenex, Pfizer, Ranbaxy Laboratories, Roche Holding, Samsung Biologics, Sanofi, and Synthon.

Commenting on the report, an analyst from the research team said: “One trend spurring growth is the emergence of biosimilars. At present, it has been observed that due to the increase in geriatric population, the prevalence of chronic diseases, such as rheumatoid arthritis, psoriatic arthritis, cancers, and metabolic disorders, has increased. As a result, Biosimilars will play a major role in this scenario. The increased sales of biosimilars are expected to pull down the sales of biologics during the forecast period.”

According to the report, one driver that will lead to the growth of this market is the rise in number of patent expiries. A biosimilar can be developed only after the patent expiry of the original product . Many first-generation biopharmaceuticals have expired or will expire during the forecast period. For instance, the patent of drugs such as Rituxan/MabThera, Remicade, Herceptin, Humira, Avastin, Synagis, Erbitux, and Lucentis are expected to expire during the forecast period.

Further, the report states that a major challenge for this market is the physicians' reluctance to prescribe biosimilars. Physicians are reluctant to prescribe biosimilars to patients, as mAbs cannot be substituted with these drugs. mAbs are developed using a living system or a genetically modified organism. Any minute variation in the entire process will have adverse effects on the safety and effectiveness of the final product. Biosimilars can also not be used during post-marketing surveillance as the substitution of drugs is prohibited during this period.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- - - - Biocon
- - - - Celltrion
- - - - Dr. Reddy's Laboratories
- - - - Hospira
- - - - 3SBio
- - - - Accord Healthcare
- - - - AET Biotech
- - - - Allergan
- - - - Alvartis Pharma
- - - - Amega Biotech
- - - - Amgen
- - - - Apotex
- - - - Aspen
- - - - AstraZeneca
- - - - Aurobindo Pharma
- - - - Baxter
- - - - Bharat Serums
- - - - Bio Sidus
- - - - Biogen
- - - - Bionovis
- - - - Bioton
- - - - BioXpre
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll